GRIN2B and neurodegenerative disease: There is therefore an urgent need for identification of GluN2B antagonists that are potent, highly selective, and with good oral bioavailability since NMDA receptor subunits containing GluN2B have proven to be a target of therapy for neurodegenerative diseases [109,110].